Dupilumab Linked to Increased Risk of Cutaneous T Cell Lymphoma in Atopic Dermatitis Patients: Study Dr Riya Dave23 April 2024 10:15 PM ISTResearchers have found that the use of dupilumab, a human monoclonal antibody targeting the IL-4 alpha receptor, is associated with an increased risk...
Serum Dupilumab levels fail to reveal treatment response in Atopic Dermatitis at 16 weeks Dr.Niharika Harsha B3 Nov 2022 8:00 PM ISTA new clinical study found that serum dupilumab levels do not affect treatment response and adverse effects during the first year of treatment at 16...
Dupilumab reduces exacerbations and improves FEV1 in uncontrolled, moderate-to-severe asthma Dr.Niharika Harsha B24 Oct 2022 8:00 PM ISTA recent study found that in patients having uncontrolled, moderate-to-severe asthma Dupilumab showed sustained, long-term reduction in exacerbations...
Tralokinumab and Topical Corticosteroids tied to sustained important in Atopic Dermatitis: ECZTRA 3 trial. Dr.Niharika Harsha B27 July 2022 7:00 PM ISTOver 32 weeks, it was found that continued use of tralokinumab treatment plus topical corticosteroids as needed provided progressive and sustained...
